a Objective: Recent studies reported a lower human papillomavirus 16 (HPV16) prevalence in cervical precancer among African American than Caucasian women in the general population. We assessed this relationship in women with HIV.
Introduction
Women with HIV infection have a several-fold greater risk of invasive cervical cancer [1] [2] [3] and precancer [i.e. cervical intraepithelial neoplasia 3 or more severe lesions (CIN-3þ)] [4] , as well as infection with oncogenic human papillomaviruses (oncHPV) [5, 6] , the major risk factor for cervical cancer and precancer. Although HPV16 accounts for approximately half of invasive cervical cancers in the general population [7] , HPV16 has the weakest association with changes in host immune status of any oncogenic HPV type, as measured by HIV status and CD4
þ T-cell count [8, 9] . Consistent with this, the prevalence of HPV16 found in women with CIN3þ was significantly lower among women with HIV (29%) than in women without HIV (62%) in the Women's Interagency HIV Study (WIHS) [10] and other studies [11, 12] .
Interestingly, two recent reports in the general United States (US) population indicated that the distribution of oncHPV types in cervical precancer varied by selfreported racial group. Specifically, the proportion of CIN3þ cases positive for either HPV16 or 18 was significantly lower in African American (41%) compared with Hispanic (46%) and non-Hispanic Caucasian women (60%) [13] . In a second study, African American and Hispanic women had a lower prevalence of HPV16 or 18 in CIN2þ lesions compared with Caucasian women [14] . Additional recent studies (but not all) found low HPV16 and sometimes also HPV18 among African Americans in the general population, even in the absence of cervical precancer [15] [16] [17] [18] [19] [20] . One prior study in women with HIV by Whittemore et al. in 2016 [20] did not find similar racial differences, but studied young individuals, 13-26 years of age, without cervical precancer. Therefore, the objective of the current study was to assess for differences in HPV16 prevalence in women with HIV and CIN-3þ across racial and ethnic groups, and for the first time to use genomic Ancestry Informative Markers (AIMs) as an adjunct to self-report to optimally characterize these racial and ethnic groups.
Methods
The WIHS is an ongoing prospective cohort study of health outcomes among 2791 women with HIV and 975 women at risk for HIV, enrolled from six clinical sites across the United States, during 1994-1995 and again during 2001-2002. As previously described [21, 22] , semi-annual visits include a gynecologic examination with specimen collection, including a Pap test and cervicovaginal lavage for HPV testing, using a well established PCR assay [5, 23] . All cervical cytology was centrally interpreted using the 1991 or 2001 Bethesda System criteria for cytologic diagnosis [24, 25] . Colposcopy was required for any epithelial cytologic abnormality, including borderline lesions (ASC-US). HPV DNA PCR detection methods in the WIHS have been described previously [5, 23, 26] . In brief, HPV DNA was detected using a well established degenerate primer MY09/MY11/HMBO1 PCR assay. Primer set PC04/ GH20, which amplifies a cellular ß-globin DNA fragment, was used as an internal control to assess the adequacy of amplification. The amplification products were then probed for the presence of 'any HPV' DNA with a generic probe mixture, and probed for individual HPV types using filters hybridized with type-specific biotinylated oligonucleotides for greater than 40 individual HPV DNA types. ß-globin-negative specimens were excluded. Written informed consent was obtained from all participants, and the study was approved by each local institutional review board. The analysis included all women in the WIHS who were diagnosed with CIN3þ through visit 35 (up to 17 years of follow-up).
Racial and ethnic groups were based on genomic ancestry informative markers (AIMs), as previously reported [27, 28] , and secondarily by self-report. Briefly, a genome-wide association study (GWAS) was conducted amongst WIHS women who provided informed consent for genetic testing (n ¼ 3353). Race/ethnicity was assessed using principal components analysis of 185 independent AIMs single nucleotide polymorphisms (SNPs) from across the human genome known to differ in allele frequency between the major racial/ethnic groups common in the WIHS.
Descriptive statistics were used to examine differences in characteristics between women with HIV to those without HIV at the time of histologic diagnosis of CIN3þ, using the t-test (to assess means), Wilcoxon test (for medians), or Pearson x 2 test (for proportions). Fisher's exact test was used to compare differences in type-specific HPV by race and ethnicity. Multivariate logistic regression was used to explore the association of race/ethnicity with HPV16 infection, after adjusting for race and other established cervical risk factors.
Results
Overall, 2791 women with HIV and 975 women at risk for HIV were enrolled in WIHS. CIN3þ was found in 154 (5.5%) women with HIV and 21 (2.2%) women without HIV across all 35 visits analyzed; this comprises a total of 62 178 person-visits (a median of 18 personvisits). Two HIV-infected women had invasive cancer. Table 1 shows selected demographic and clinical characteristics at the time of diagnosis of CIN3þ. Women without HIV were on average younger and more likely than women with HIV to be less than 30 years of age.
Of the 175 women diagnosed with CIN3þ, AIMs data were available in 168 (96%). The HPV type-specific distribution by race among all CIN3þ cases is shown in Table 2 . A total of 54 (31%) cases of CIN3þ were associated with HPV16 infection and 17 (10%) were associated with HPV18. However, African American (27%) and Hispanic (37%) women were significantly less likely than Caucasian (62%) women to have HPV16-associated CIN3þ (P ¼ 0.01). The prevalence of HPV18 did not differ by racial or ethnic group.
In multivariate logistic regression analysis among all women with CIN3þ (Supplemental Table 1 , HPV16 prevalence in black women with CIN-3R Keller et al. 2823 Table 1 . Demographic and clinical characteristics at diagnosis of women with cervical intraepithelial neoplasia three or more severe lesions by HIV status and CD4 R count. http://links.lww.com/QAD/B368), those with HIV were significantly less likely than women without HIV to test positive for HPV16, after adjustment for multiple relevant covariates, including age, race/ethnicity based on AIMs data, WIHS enrollment period, smoking, lifetime number of sexual partners, number of sexual partners in the 6 months before CIN3þ diagnosis, current CD4 þ count, and history of AIDS (consistent with our prior report) [10] . A very high life-time (but not recent) number of sex partners was also associated with HPV16-positive CIN-3þ. Moreover, in these same models, African American women with CIN3þ were approximately 85% less likely to have HPV16 detected compared with Caucasian women [odds ratio (OR) 0.13, 95% confidence interval (CI) 0.04-0.44, P ¼ 0.001; Supplemental Table 1 , http://links.lww.com/QAD/ B368). Hispanic ethnicity, however, was not significantly associated with HPV16 detection in multivariate analysis (P ¼ 0.81), and the prevalence of no other oncHPV type differed significantly by race/ethnicity in multivariate models that excluded the category 'Other.' Similar associations were observed for women who self-reported their race as African American (OR 0.07, 95% CI 0.02-0.27, P < 0.0001). There was high concordance for race using AIMs data versus self-report among women with CIN3þ (kappa ¼ 0.63, 95% CI 0.53-0.72) and for all WIHS patients with available HPV data (kappa ¼ 0.72, 95% CI 0.70-0.74).
There were no racial differences in HPV16 prevalence among all WIHS women (including all women with and without cervical disease). That is, a lower HPV16 prevalence among African American women with HIV was only observed in the setting of cervical disease. Importantly, the findings did not change when the definition of precancer was expanded to include not only WIHS women with CIN3þ, but also the subset of CIN2 confirmed by concomitant high-grade squamous intraepithelial lesion (HSIL) of the severe subtype -a total of N ¼ 250 women (Supplemental Table 2 , http://links. lww.com/QAD/B368).
Discussion
Recent studies, including population-based investigations, have reported a lower prevalence of HPV16, and sometimes HPV18, in African American women with and without cervical precancer [13, 14, [16] [17] [18] . This could potentially lead to increased precancer risk in African Americans immunized with quadrivalent or bivalent HPV vaccines targeting HPV16/18 but not other oncHPV types, relative to HPV vaccine-immunized Caucasian women. The current study, however, was the first, to our knowledge, to study these relationships in women living with HIV, a population at high risk Table 2 . Type-specific human papillomavirus prevalence in women with cervical intraepithelial neoplasia 3 or more severe lesions using genomic ancestry informative markers to characterize racial and ethnic groups, N (%). for cervical precancer and cancer compared with women without HIV. The results showed markedly lower odds of HPV16-positive precancer amongst African American than Caucasian women even after accounting for HIV status and CD4 þ count. Some studies in the general population also found reduced HPV16 prevalence in Hispanics [13, 14, 29] . Although our data in Hispanic versus Caucasian women living with HIV were suggestive of such an association it did not reach significance in this analysis, after adjusting for covariates.
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These results are particularly noteworthy as recent metaanalysis showed that HPV16 was less prevalent among HIV-positive than HIV-negative cervical cancer (in Africans) and precancer patients (worldwide) [11, 12] . The current data additionally show that, even among HIV-positive women with cervical precancer, those of African descent are more likely to test positive for HPV types other than HPV16, than Caucasian women. Future US studies in a larger multiracial HIV-positive population, involving laser capture microdissection, would be useful in confirming these findings. Possible reasons for a low HPV16 prevalence in African Americans with HIV and precancer include racial differences in distribution and prevalence of HPV infection within sexual networks, host susceptibility, and differential ability to clear HPV infection [15, 19] .
Overall, if the single most important factor determining HPV vaccine effectiveness is the HPV types targeted, then these data suggest that use of the nonavalent is preferable to either the quadrivalent or bivalent vaccine. On the other hand, immunogenicity has been shown to be greater with the bivalent vaccine [30, 31] , which may be important in immunosuppressed populations. Recent data also show that even if precancer in HIV-positive women involves a greater diversity of HPV types compared with the general population [10, 11] , the proportion of HPV16 infection that progresses to cervical precancer (and possibly cancer) is far higher than other oncHPV types [23] . The optimal approach for HPV vaccination and for primary HPV screening (in which an HPV assay and not cytology is the initial test) has not been fully determined in HIV-positive women, and cannot be adequately extrapolated from studies in the general population.
